Company intelligence / Profile preview

Guardaya

Stockholm, Sweden

Ownership: Private
Development stage: Other

Overview

Guard Therapeutics is developing RMC-035 to protect kidneys from injury during procedures like open-heart surgery. It has received FDA IND clearance and Fast Track Designation.

Therapeutic areas: Nephrology
Modalities: Peptides
Industry: Biotech

Beyond the preview

Go deeper on Guardaya.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Guardaya.

Explore the full profile